Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
AN2 Therapeutics Inc (ANTX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/05/2025: ANTX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $1.5
1 Year Target Price $1.5
| 0 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 79.7% | Avg. Invested days 53 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 11/05/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 31.17M USD | Price to earnings Ratio - | 1Y Target Price 1.5 |
Price to earnings Ratio - | 1Y Target Price 1.5 | ||
Volume (30-day avg) 3 | Beta -0.04 | 52 Weeks Range 0.97 - 1.68 | Updated Date 11/6/2025 |
52 Weeks Range 0.97 - 1.68 | Updated Date 11/6/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.25 |
Earnings Date
Report Date 2025-11-06 | When - | Estimate -0.315 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -26.54% | Return on Equity (TTM) -44.71% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -27938509 | Price to Sales(TTM) - |
Enterprise Value -27938509 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -2.11 | Shares Outstanding 27326165 | Shares Floating 17712547 |
Shares Outstanding 27326165 | Shares Floating 17712547 | ||
Percent Insiders 25.47 | Percent Institutions 39.58 |
Upturn AI SWOT
AN2 Therapeutics Inc
Company Overview
History and Background
AN2 Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. It was founded in 2018 and is headquartered in Menlo Park, California. The company's pipeline is centered around developing and commercializing treatments to address significant unmet medical needs in infectious diseases.
Core Business Areas
- Infectious Disease Therapeutics: Focuses on the development and commercialization of therapeutics for rare, chronic, and serious infectious diseases.
Leadership and Structure
The leadership team includes prominent figures in the pharmaceutical industry with experience in drug development and commercialization. The organizational structure is typical of a biopharmaceutical company, with departments focused on research, development, clinical trials, and commercial operations.
Top Products and Market Share
Key Offerings
- Epetraborole: Epetraborole is AN2 Therapeuticsu2019 lead product candidate, an investigational treatment for patients with nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium abscessus. No market share data is available as it is in development. Competitors include Insmed (AREXVY) and various off-label antibiotic regimens. The total addressable market for Mycobacterium abscessus is substantial, with limited approved therapies.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and characterized by significant investment in research and development. The market for infectious disease treatments is growing, driven by increasing prevalence of drug-resistant infections and a need for new therapies.
Positioning
AN2 Therapeutics is positioned as a company focused on addressing unmet needs in rare infectious diseases. Its competitive advantage lies in its novel approach to treating Mycobacterium abscessus.
Total Addressable Market (TAM)
The estimated TAM for NTM lung disease treatment is significant, potentially reaching hundreds of millions of dollars annually. AN2 is positioned to capture a portion of this market if Epetraborole is approved.
Upturn SWOT Analysis
Strengths
- Novel therapeutic approach for NTM lung disease
- Experienced management team
- Focus on unmet medical needs
Weaknesses
- Reliance on a single lead product candidate
- Early-stage development company with no currently approved products
- High risk associated with drug development
Opportunities
- Potential for FDA approval of Epetraborole
- Expansion into other infectious disease indications
- Partnerships with larger pharmaceutical companies
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other companies developing NTM therapies
- Patent challenges
Competitors and Market Share
Key Competitors
- INSM
- TBIO
- BPMC
Competitive Landscape
AN2 Therapeutics competes with companies developing therapies for mycobacterial infections. Its advantage lies in its novel approach to targeting M. abscessus. The competitors listed are developing or have developed treatments for similar diseases and conditions.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to the company being in the development stage.
Future Projections: Future growth is dependent on successful clinical trials and regulatory approval of Epetraborole. Analyst estimates project significant revenue growth if the drug is approved.
Recent Initiatives: Recent initiatives include advancing clinical trials for Epetraborole and seeking regulatory approval.
Summary
AN2 Therapeutics is a development-stage biopharmaceutical company with a focus on rare infectious diseases. The company's success hinges on the clinical and regulatory success of its lead product candidate, Epetraborole. While there are significant risks associated with drug development, the company is targeting an area of high unmet need. AN2 needs to secure regulatory approvals and overcome competition from established pharmaceutical companies.
Similar Stocks
Sources and Disclaimers
Data Sources:
- AN2 Therapeutics Investor Relations
- SEC Filings
- Analyst Reports
- Company Website
Disclaimers:
This analysis is based on publicly available information and does not constitute financial advice. Investing in biopharmaceutical companies is inherently risky. Market share percentages are estimated as there is not a single specific market share data source at this time.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About AN2 Therapeutics Inc
Exchange NASDAQ | Headquaters Menlo Park, CA, United States | ||
IPO Launch date 2022-03-25 | Co-Founder, CEO, President & Chairman of the Board Mr. Eric E. Easom | ||
Sector Healthcare | Industry Biotechnology | Full time employees 22 | Website https://www.an2therapeutics.com |
Full time employees 22 | Website https://www.an2therapeutics.com | ||
AN2 Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics. The company's initial candidate includes epetraborole, which is phase 3 clinical trial as a once-daily oral treatment for patients with non-tuberculous mycobacterial lung disease, as well as studying for the treatment of acute melioidosis. It also develops AN2-502998 (AN15368), an investigational, boron-based small molecule in development for the treatment of chronic Chagas disease that is in preclinical trials; and has various research programs targeting the development of novel compounds in oncology and infectious disease based on its boron chemistry platform. It has a license agreement with Anacor Pharmaceuticals, Inc. to use, develop, manufacture, commercialize compounds and products, including epetraborole for the treatment, diagnosis, or prevention of various human diseases; and Brii Biosciences Limited to research, develop, manufacture, and commercialize compounds and products comprising epetraborole in China, Hong Kong, Taiwan, and Macau for the diagnosis, treatment, and prevention of human diseases. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.